Axcella Health (NASDAQ:AXLA - Get Rating) had its price target dropped by stock analysts at HC Wainwright from $10.00 to $8.00 in a note issued to investors on Wednesday, The Fly reports. We are a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. And finally, in OHE, we plan to provide an update on enrollment in our EMMPOWER trial later this year. Thanks. Privacy Policy and Those impacted often describe the condition as crushing. Weve also added a couple of new members of our executive committee in recent months to maintain our strong track record. and good morning, everyone. I will then preview what we expect will be a transformative 2022 as we approach important clinical data readouts and other key milestones that are now on the near-term horizon. Symbols Close Price Percentage Volume RSI Div EPS Company Name Company Business Description Company Website Date of Incorporation Sizzle Index Entered Tonite 0 AAQC/WS 0.020100 -43.06% 18197 26.181900 True 1 ABMBF 0.032000 -3.03% 30000 Good morning, just a question about the FDA and their current priorities in terms of COVID and Long-COVID, since we have seen a change over the last year from approvals based on emergency use to shifting towards full trials and Long-COVID being a recent development. AXCELLA HEALTH INC Vice President of Investor Relations, Vice President of Corporate Marketing and Communications, Vice President of Investor Relations Salaries with a Bachelor's Degree, Vice President of Investor Relations Salaries with a Master's Degree or MBA, Vice President of Investor Relations Salaries with a JD, MD, PhD or Equivalent, Detailed skills and competency reports for specific positions. Investor Activity Axcella Health has actively raised capital from investors. Jan. 11, 2022 2:26 PM ET Axcella Health Inc. (AXLA) 1 Like. And then I have a follow-up. All forward-looking statements represent our views as of today, March 30, 2022 and should not be relied upon as representing our views as of any subsequent date. No representations and warranties are made as to the reasonableness of the assumptions. I would like to turn the conference back over to CEO, Bill Hinshaw, for any closing remarks. You can think the PCR like the battery health indicator in your smartphone. So, thank you, operator, and thanks to everyone who tuned in today. Average salaries for Axcella Health Vice President Investor Relations: [salary]. These charts show the average base salary (core compensation), as well as the average total cash compensation for Vice President of Investor Relations in companies like AXCELLA HEALTH INC in the United States. Axcella Health is a biotechnology company that researches and develops novel multifactorial interventions to support health and address dysregulated metabolism. Thank you for taking the question. HC Wainwright Adjusts Axcella Health's Price Target to $10 From $8, Maintains Buy Rating . Yes, appreciate the color. Here's what investors need to know about the announcement. [Operator Instructions] The first question comes from Ed Arce with H.C. Wainwright & Company. So, yes, its going very well. We are also intent on expanding our pipeline by leveraging key learnings on the research side of our business and emerging science. Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Find out what this means for you and get the rest of the rankings on AXLA! Axcella Health (AXLA) Investor Presentation - Slideshow. As of September 29, 2022, Axcella Health Inc had a $91.1 million market capitalization, putting it in the 30th percentile of companies in the Biotechnology & Medical Research industry. Quote Chart Stock Analysis News . This concludes our question-and-answer session. What I can share with you is that the FDA and other health authorities around the world have obviously been exceptionally responsive to dealing with the pandemic, working collaboratively with the companies while maintaining a high standard quality. Axcella Health Inc (AXLA) shares closed today at 1.6% above its 52 week low of $1.85, giving the company a market cap of $73M. Currently, Axcella Health Inc's price-earnings ratio is . The timing of that is what we will then be working on in determining in the next steps. Axcella Health ( NASDAQ:AXLA - Get Rating) had its price objective reduced by research analysts at HC Wainwright from $10.00 to $8.00 in a research note issued to investors on Wednesday, The Fly . Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Okay. The next question comes from Thomas Smith with SVB Leerink. And so the needs there are evolving. Thank you, Jason and good morning, everyone. You may now disconnect. Based on 580,011 investor portfolios analyzed by TipRanks. I know we have heard from some other companies enrolling these paired biopsy studies that they have seen some slowdowns. Provide specific products and services to you, such as portfolio management or data aggregation. Investor Relations Events & Presentations Download Presentation View all events Recent News. MA 02139, O: 857-320-2200 EMMs encompass a broad set of molecular families, including amino acids and their derivatives. In order to meet our inclusion criteria, subjects in this trial must have a PCR recovery time of at least 50 seconds, so at least double the norm. The market has been high on Axcella Health Inc stock recently. Does the cash runway guidance take into account the recent $25 million equity raise? Please go ahead, sir. Their latest funding was raised on Oct 13, 2022 from a Post-IPO Equity round. This belief stems both from our preclinical and our clinical work. Axcella Health Inc. AXLA was a big mover last session, as the company saw its shares rises more than 5% on the day.The move came on solid volume with far more shares changing hands than in a . In terms of Long-COVID, yes, we are very excited for closing enrollment and then the data. At Axcella, we are seeking to unlock the full potential of EMMs by combining a deep understanding of biological pathways with recent advances in systems biology and machine learning. The table shows changes in AXLA in the past 3 months by investors with public portfolios. Okay. CA. The Axcella Health stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. Axcella Health Inc has a Bullish sentiment reading. Develops major goals to support broad functional objectives. No cash balance or cash flow is included in the calculation. About; EMMs; Platform; Pipeline; Investors & News Axcella Health Stock Investors. Sure. Oxford was specifically chosen for two key reasons. Investor Relations Axcella Health Inc AXLA Stock Quote Morningstar Rating . So let me share a little further background on the three trials that we have in motion here at Axcella. View . Preo das aes, anlise fundamental e guia passo a passo para a compra de aes da Axcella Health Inc. (AXLA) sem pagamento de comisses. I will build on that and say this is exactly as Margaret outlined a clear study to demonstrate the mechanism and the direction of the impact in a statistical fashion. What is distinct about COVID is the number of people who have persistent symptoms, like long-standing debilitating fatigue. Axcella Health Inc's trailing 12-month revenue is $0.0 million with a % profit margin. As you know, Omicron has really only been on us since December, so at least in the United States and UK, it was a bit earlier. Is this happening to you frequently? Hello, good morning. 19, 2022 1:42 PM ET Axcella Health Inc. (AXLA) SA Transcripts. It also underperformed . General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. The Cambridge, Mass.-based biotechnology company's shares started trading on the Nasdaq Global Market under the ticker AXLA on May 9. Distinguished Service Professor & Higginson Professor of Physiology and Medicine, Harvard Medical School, Director, Sarah W. Stedman Nutrition and Metabolism Center Director, Duke Molecular Physiology Institute, Cleveland Family Professor of Pediatric Research Professor of Human Genetics University of Pittsburgh, 840 Memorial Drive, Get the latest business insights from Dun & Bradstreet. How much does a Vice President of Investor Relations make at companies like AXCELLA HEALTH INC in the United States? And any sense for evolving or changes to the patients as additional variants of COVID emerge? Investor's Business Daily 06/27/2022 04:47 PM ET. We continue to help the investigators by providing the latest information about how to minimize the screen failure rate, which is always challenging in these trials. PCR is a very quantitative and precise measure of our ability to improve mitochondrial function. Salary ranges can vary widely depending on many important factors, including education, certifications, additional skills, the . I am wondering if you could give us some detail on exactly what was eased and if that would affect any other parts of design of the study. Got it. Investor Relations . E: info@axcellatx.com. The end result: Multi-targeted EMM compositions with the potential to address the unmet medical needs of patients with a range of complex conditions. Thank you. Today, I plan to briefly recap what was the year of foundation lane and strong execution in 2021. Bob is a more recent addition having joined Axcella in February. , Axcellas net loss for the quarter and year ended December 31, 2021 was $17.9 million or $0.46 per share and $64.6 million or $1.70 per share, respectively. So, we required this to be within the previous 24 weeks, and the investigators were noting that while they were having individuals come in with clear-cut histories of OHE, they were simply unable to obtain that documentation. Consulting, Boston, MA panies on growth and operational Economics, Philadelphia, PA Associate Consultant 2017-2018, strategies, including Medicare and Research Assistant, 2017-Present Associate 2015-2017 Medicaid . So, those are thats just an example of some of the changes we made. Given its multi-targeted mechanism and multifactorial activity, its oral route of administration and its safety and tolerability to date, we believe EMMPACT could firmly establish 1125 as an ideal first-line NASH candidate. Compensation data tools, salary structures, surveys and benchmarks. In terms of regulatory activities, as you are familiar, we had an excellent interaction with the MHRA, which allowed us to open the trial quickly. The end result: Multi-targeted EMM compositions with the potential to address the unmet medical needs of patients with a range of complex conditions. Thanks for asking that question. All of these efforts set us up for what we expect will be a momentous 2022. Find company research, competitor information, contact details & financial data for Axcella Health Inc. of Cambridge, MA. Good morning, ladies and gentlemen and welcome to Axcellas Fourth Quarter and Year End 2021 Conference Call. 40 subjects with Long-COVID fatigue and muscle weakness are being enrolled in this trial and are receiving either AXA1125 or placebo for 28 days.